First Komzifti Sale Triggers $135M Kura Oncology Payout
Kura Oncology has recorded the first U.S. commercial sale of Komzifti (ziftomenib), its once-daily oral menin inhibitor approved on...
eClinical Tech News
Newgen Reports Powerful Growth, NAV Strengthened to $66.75
NewgenIVF Group reported a sharp swing to profitability for the first nine months of 2025, posting $17.5 million in...
PEDMARK® Study in Japan Shows Positive Hearing Loss Results
Fennec Pharmaceuticals reported positive topline results from the investigator-initiated STS-J01 Phase 2/3 study in Japan evaluating Pedmark (sodium thiosulfate)...
Animal-Free Alpha-Lactalbumin Deal Signed by Dyadic & BRIG
Dyadic Applied Biosolutions and Brig Bio have signed a development and commercialization agreement to produce recombinant bovine alpha-lactalbumin using...
7Urgent Reminder: Adverum Stockholders Tender Shares to Lilly
Eli Lilly has launched a tender offer to acquire Adverum Biotechnologies for $3.56 per share in cash plus a...
Rakovina Therapeutics Reports Q3 2025 Financial Results
Rakovina Therapeutics reported Q3 2025 results alongside a slate of preclinical updates, highlighting progress across its AI-enabled DNA damage...
Scilex Completes Valuable Two-Tranche Investment in Datavault
Scilex Holding Company has closed the second tranche of its strategic investment in Datavault AI, funding the purchase of...
Hutchmed Highlights Clinical Data at 2025 ESMO & ASH Meetings
HUTCHMED will field a broad slate of oncology and hematology data at ESMO Asia and ASH 2025, spotlighting multiple...
HUTCHMED Highlights Clinical Data for ESMO & ASH Meetings
HUTCHMED will bring a broad slate of oncology and hematology readouts to ESMO Asia (December 5–7, Singapore) and ASH...
Bioversys Doses First Subjects in BV100 Phase 1 China Trial
BioVersys has dosed the first healthy volunteer in a China-based Phase 1 study of BV100, an intravenous rifabutin formulation...